Company Analysis
Sign in

Coya Therapeutics, Inc. (COYA)

Nasdaq: COYA · Pharmaceutical Preparations · Houston, TX · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.5
◀ Past 4.4● Present 4.6▶ Future 6.9
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Coya Therapeutics, Inc.

Nine metrics read from its own filings, by tense
Headline grade
5.5/10
◀ Past4.425% of the headline
● Present4.635% of the headline
▶ Future6.940% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.4/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2021.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Coya Therapeutics, Inc.'s filings since 2021 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
4.1/10

What has it actually done, year after year?

4 filed years; profitable in 0 of 4.

weight 45% of this tense · 41st percentile among 323 sector filers · read for its customers

From the record

Coya Therapeutics, Inc.'s 4 filed years say what it did: it rose in 1 of 2 years; the deepest fall was 41% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 4 of those years (its annual reports).

What it rests on

  • the share of years revenue rosebottom 36% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak40.8%top 41% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
2.3/10

How has it treated the people who own it?

SI estimate 2.3/10, confidence 35 of 100 (one part).

weight 33% of this tense · 23rd percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 23% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Coya Therapeutics, Inc.'s shareholder treatment is put at 2.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 23% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.6/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
6.3/10

Is it financially healthy right now?

ROE -49%: lost 49¢ per shareholder dollar. Leverage 14%: owes 14¢ per asset dollar.

weight 45% of this tense · 64th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Coya Therapeutics, Inc. lost about 49 cents for every dollar of shareholders' money. Leverage: it owed about 14 cents per dollar of assets, and net share issuance: its share count grew 9.8% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 23% of its family
  • return on equitytop 49% of its family
  • the share count against the year beforetop 38% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
4.2/10

How strong is its position in its industry?

bottom 42% of 315 in its family; net margin -267.1%.

weight 22% of this tense · 42nd percentile among 315 sector filers · read for its customers

From the record

Coya Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $8 million in fiscal 2025 ranks in the bottom 40% by size; a net margin of -267.1% ranks in the bottom 43% (its annual reports).

What it rests on

  • revenue against the family$7.9Mbottom 40% of its family
  • net margin-267.1%bottom 43% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
2.5/10

What are the people in charge doing?

bottom 25% of 315 in its family for leadership; chief executive since 2024.

weight 33% of this tense · 25th percentile among 315 sector filers · read for its shareholders

From the record

Coya Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Swaminathan, Arun (Chief Executive Officer, as filed), filing under that title since 2024-11-12, 2 years (bottom 23% of its family); most of the 10 officers and directors filing now have filed since the record of its people begins (2022-12-28), a floor of 3.6 years the record cannot see past, so that part is not read; 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge7 in three years among 10 peoplebottom 26% of its family
  • the chief executive's years on the record2.0 yearsbottom 23% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

6.9/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed
6.7/10

How much room does it have to grow?

top 33% of 273 in its family for room to expand.

weight 33% of this tense · 67th percentile among 273 sector filers · read for itself

From the record

Coya Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $47 million against no long-term debt tagged leaves 93.7% of its assets as net cash, top 6% of its family; cash from operations less capital spending is -135.2% of revenue (bottom 47%); research spending of 210.6% of revenue (top 41%) (its annual report).

What it rests on

  • cash less debt against assets93.7%top 6% of its family
  • cash from operations less capital spending against revenue-135.2%bottom 47% of its family
  • research spending against revenue210.6%top 41% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
8.9/10

What could actually drive growth from here?

top 11% of 306 in its family for growth drivers.

weight 45% of this tense · 89th percentile among 306 sector filers · read for its customers

From the record

Coya Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 123.7% (top 14%); research spending grew 55.9% a year (top 7%) (its annual reports). Coya Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • the newest year's revenue growth123.7%top 14% of its family
  • three-year growth of research spending55.9%top 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
3.2/10

Did its newest year beat what its own record pointed to?

bottom 32% of 233 in its family for expectations against reality.

weight 22% of this tense · 32nd percentile among 233 sector filers · read for its shareholders

From the record

Coya Therapeutics, Inc.'s newest year against its own record: net income of $21 million against a prior three-year average of $12 million (bottom 17%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 47%) (its annual reports).

What it rests on

  • net income against the prior three years' average-81%bottom 17% of its family
  • net margin against its prior average+8.8 pointsbottom 47% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton COYA · research, not advice